Stocks
Heron Therapeutics, Inc.HRTX
NASDAQHealthcareBiotechnology$0.32-4.98%
Price as of · delayed, not real-time
Focused on developing novel therapies to address unmet medical needs, this biopharmaceutical company specializes in oncology and pain management. Its flagship products include FDA-approved treatments for chemotherapy-induced nausea and vomiting, as well as post-operative pain. Investors monitor its pipeline and commercialization efforts due to its potential in niche markets.
Market Cap: $139.3M52W Range: $0.30-$1.58
Congressional Interest in Heron Therapeutics, Inc. (HRTX)
2 members of Congress have disclosed 2 trades in Heron Therapeutics, Inc. (HRTX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
0
Sells
2
Who in Congress Is Trading HRTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-08-04 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2021-03-31 | Ashley Hinson Arenholz | sell | $1K-$15K |